Literature DB >> 23322888

Absence of airway secretion accumulation predicts tolerance of noninvasive ventilation in subjects with amyotrophic lateral sclerosis.

Nadia Vandenberghe1, Anne-Evelyne Vallet, Thierry Petitjean, Pierre Le Cam, Stéphane Peysson, Claude Guérin, Frédéric Dailler, Sylvie Jay, Vincent Cadiergue, Françoise Bouhour, Isabelle Court-Fortune, Jean-Philippe Camdessanche, Jean-Christophe Antoine, François Philit, Pascal Beuret, Sylvie Bin-Dorel, Christophe Vial, Emmanuel Broussolle.   

Abstract

OBJECTIVE: To assess factors that predict good tolerance of noninvasive ventilation (NIV), in order to improve survival and quality of life in subjects with amyotrophic lateral sclerosis.
METHODS: We conducted a prospective study in subjects with amyotrophic lateral sclerosis and requiring NIV. The primary end point was NIV tolerance at 1 month. Subjects, several of whom failed to complete the study, were classified as "tolerant" or "poorly tolerant," according to the number of hours of NIV use (more or less than 4 h per night, respectively).
RESULTS: Eighty-one subjects, 73 of whom also attended the 1-month follow-up visit, participated over 34 months. NIV tolerance after the first day of utilization predicted tolerance at 1 month (77.6% and 75.3% of subjects, respectively). Multivariate analysis disclosed 3 factors predicting good NIV tolerance: absence of airway secretions accumulation prior to NIV onset (odds ratio 11.5); normal bulbar function at initiation of NIV (odds ratio 8.5); and older age (weakly significant, odds ratio 1.1).
CONCLUSION: Our study reveals 3 factors that are predictive of good NIV tolerance, in particular the absence of airway secretion accumulation, which should prompt NIV initiation before its appearance.

Entities:  

Keywords:  airway secretion accumulation; amyotrophic lateral sclerosis; cohort studies; mechanically assisted cough; noninvasive ventilation tolerance; prognosis

Mesh:

Year:  2013        PMID: 23322888     DOI: 10.4187/respcare.02103

Source DB:  PubMed          Journal:  Respir Care        ISSN: 0020-1324            Impact factor:   2.258


  6 in total

1.  Lung Insufflation Capacity with a New Device in Amyotrophic Lateral Sclerosis: Measurement of the Lung Volume Recruitment in Respiratory Therapy.

Authors:  Keisuke Yorimoto; Yosuke Ariake; Takako Saotome; Madoka Mori-Yoshimura; Tadashi Tsukamoto; Yuji Takahashi; Yoko Kobayashi
Journal:  Prog Rehabil Med       Date:  2020-05-26

2.  Noninvasive ventilation improves sleep in amyotrophic lateral sclerosis: a prospective polysomnographic study.

Authors:  Bart Vrijsen; Bertien Buyse; Catharina Belge; Wim Robberecht; Philip Van Damme; Marc Decramer; Dries Testelmans
Journal:  J Clin Sleep Med       Date:  2015-04-15       Impact factor: 4.062

Review 3.  Continuous noninvasive ventilation for respiratory failure in patients with amyotrophic lateral sclerosis: current perspectives.

Authors:  Giuseppe Fiorentino; Anna Annunziata; Anna Michela Gaeta; Maurizia Lanza; Antonio Esquinas
Journal:  Degener Neurol Neuromuscul Dis       Date:  2018-09-04

4.  Thick Mucus in ALS: A Mixed-Method Study on Associated Factors and Its Impact on Quality of Life of Patients and Caregivers.

Authors:  Sarah K Bublitz; Eva Mie; Maria Wasner; Alexander Hapfelmeier; Jens Geiseler; Stefan Lorenzl; Andrea Sylvia Winkler
Journal:  Brain Sci       Date:  2022-02-11

5.  Developing an intrasalivary gland botox service for patients receiving long-term non-invasive ventilation at home: a single-centre experience.

Authors:  Jessica Harbottle; Hannah Carlin; Thomas Payne-Doris; Hilary M I Tedd; Anthony de Soyza; Ben Messer
Journal:  BMJ Open Respir Res       Date:  2022-02

6.  Predictive factors for prognosis after gastrostomy placement in routine non-invasive ventilation users ALS patients.

Authors:  Adèle Hesters; Maria Del Mar Amador; Rabab Debs; Nadine Le Forestier; Timothée Lenglet; Pierre-François Pradat; François Salachas; Morgane Faure; Maria-Alejandra Galarza Jimenez; Jesus Gonzalez-Bermejo; Capucine Morelot; Gaëlle Bruneteau
Journal:  Sci Rep       Date:  2020-09-15       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.